Summit Therapeutics Inc is a biopharmaceutical company based in Menlo Park, CA, dedicated to addressing serious, unmet medical needs in the field of oncology. Their mission is to improve overall human health by providing innovative therapies for oncology patients facing challenging diagnoses. Summit is currently conducting two Phase III clinical trials for their lead candidate, ivonescimab, a potential first-in-class investigational bispecific antibody that combines immunotherapy and anti-angiogenesis effects in a single molecule.
With a focus on non-small cell lung cancer (NSCLC), Summit aims to enhance patient outcomes and quality of life through the development of ivonescimab. The company has partnered with Akeso, Inc. for the discovery and clinical development of this novel therapy, which has shown promising results in clinical studies conducted in China and Australia. Summit's commitment to growth and innovation drives their efforts to bring their mission into reality and expand the potential of ivonescimab to treat additional solid tumors in the future.
Generated from the website
